Experimental CLL drug cirmtuzumab tested for safety in retreatment
NCT ID NCT02860676
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tested the safety of cirmtuzumab, an experimental antibody that targets a protein called ROR1 found on CLL cancer cells but rarely on healthy cells. Only 3 people with CLL who had previously received cirmtuzumab were retreated for 6 to 12 months. The main goal was to see if the drug is safe and tolerable, not whether it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cirmtuzumab (a monoclonal antibody that targets ROR1 on cancer cells)
What this could lead to
If it works, this could point toward a safer retreatment option for CLL that spares healthy cells.
What could go wrong
This is a very early, tiny study (only 3 people) focused on safety, not effectiveness. It may not work in humans or may have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UC San Diego Moores Cancer Center
La Jolla, California, 92093, United States